NerPharMa - Part of NMS Group
Claudio Salvagnini is a seasoned leader and consultant with extensive experience in business transformation and sustainable practices. Currently serving as a Board Member, Deputy CEO, and Interim Manager at NerPharMa since January 2023, Claudio also co-founded Stellio in May 2014, focusing on sustainable change through responsible consulting and team-building activities. Additional roles include Consultant for Strategic Sourcing and Partnership at UNIVERCELLS, Head of New Businesses and Pipeline Development at Polpharma, and Director of Sales Marketing Business Development at MINAKEM. Claudio's academic background includes a PhD in Organic Synthesis and Biomaterials from Université catholique de Louvain, complemented by a degree in Chemistry from Università degli Studi di Padova and further studies at the University of Strathclyde.
This person is not in the org chart
This person is not in any teams
NerPharMa - Part of NMS Group
NerPharMa operates as a Contract Development and Manufacturing Organization and is characterized by a strong specialization in oncology with important know-how and the highest quality standards. More than 100 selected and specialized employees working at NerPharMa, in two different teams: NerPharMa DP dealing with the development and manufacturing of compounds, injectables and solid oral for various therapeutic areas, with handling of cytotoxic and cytostatic finished products and activities of formulation, packaging and distribution and NerPharMa DS dealing with the development and production of active principles only oncological moving from laboratory scale to commercial products.